This article is published in The Lancet Global Health
In 1975–99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance. This paper studies the research and development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011.
The study finds that of the 850 new therapeutic products registered in 2000–11, 37 (4%) were indicated for neglected diseases, comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting for 1% of the 336 new chemical entities approved during the study period. This continued ‘fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.
Belen Pedrique, Nathalie Strub-Wourgaft, Claudette Some, Piero Olliaro, Patrice Trouiller, Nathan Ford, Bernard Pécoul, Jean-Hervé Bradol